Artal Group’s Third Harmonic Bio THRD Stock Holding History

Artal Group’s Portfolio THRD Stock Details THRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-200,000	Closed	-$3.79M	–	136
2022 Q3	$3.79M	Buy	+200,000	New	+$3.6M	0.16%	69

Other funds holding THRD

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artal Group's THRD Position: Q4 2022 in Review

Artal Group sold out of Third Harmonic Bio (THRD) in Q4 2022, closing a stake of 200,000 shares — an estimated $3.79M sold.

Artal Group first reported a position in THRD in Q3 2022 and held it in 1 quarter. The position peaked at $3.79M in Q3 2022. 50 funds tracked by Wall St. Rank hold THRD as of Q4 2022.

Artal Group reported no remaining Third Harmonic Bio position as of Q4 2022 after selling out during the quarter.
Artal Group sold 200,000 Third Harmonic Bio shares in Q4 2022, an estimated $3.79M.
Artal Group first reported a position in Third Harmonic Bio in Q3 2022 and held it in 1 quarter.
Artal Group's Third Harmonic Bio position peaked at $3.79M in Q3 2022.
50 funds tracked by Wall St. Rank held Third Harmonic Bio as of Q4 2022.

Based on Artal Group's 13F filing for Q4 2022, filed 13 Feb 2023.